The pipeline and commercial market for novel antimicrobial drugs is insufficient to address current and future patient needs or mitigate the loss of effective treatments as antimicrobial resistance spreads. The U.S. Government implements a range of efforts to ensure sustainable availability of antimicrobial treatments, supporting research, product development, and appropriate use. Opportunities remain to expand appropriate access to antimicrobial drugs domestically and globally and support the sustainable development of antimicrobial drugs into the future, despite the evolution of antimicrobial resistance.
This issue brief describes challenges in developing and sustaining availability of novel antimicrobial drugs, ongoing U.S. government efforts, and future opportunities.
*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Casey Sullivan, casey.sullivan@hhs.govv. Content will be updated pending the outcome of the Section 508 review.
Related Products: